Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.4.2: prohibited at all times. Non-Specified. [1]
S4.4.2 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulations
Insulin is medically essential in type 1 diabetes and may be needed in other diabetes settings. WADA’s diabetes guidance discusses treatment and TUE documentation. Necessary insulin must not be withheld or stopped to avoid a sport-compliance question; the treating team and responsible anti-doping body should coordinate the documentation. [2]
- This family entry is not an exhaustive inventory of insulin analogues, concentrations or devices.
Examples and warnings
The US Humalog label describes injectable insulin lispro. Administration options differ between product concentrations; severe hypoglycemia, medication errors, hypokalemia and pump failure are important risks. The US Afrezza label describes inhaled human insulin and adds a boxed warning about acute bronchospasm in chronic lung disease. Inhaled through the mouth does not mean swallowed as a tablet. [3] [4]
- Products, concentrations, routes and delivery devices are not automatically interchangeable. No dose recommendations are provided.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- WADA TUE Physician Guidelines: Diabetes Mellitus, version 6.0 ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Relevant cited sections
- DailyMed HUMALOG insulin lispro prescribing information ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
- DailyMed AFREZZA human insulin inhalation powder label ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.